

TOPICAL CORTICOSTEROID POTENCY

Topical steroid preparations are grouped according to relative anti-inflammatory activity, but activity may vary considerably depending upon the vehicle, the site of application, disease, the individual patient and whether or not an occlusive dressing is used.

Relative Potency	Generic Name	Brand Name	Strength
	Desonide		0.05%
Low Potency	Hydrocortisone ¹	Cortate [®] , Unicort [®]	0.5%, 1%, 2.5%
Medium Potency	Amcinonide ²		0.1%
	Betamethasone valerate ¹	Betnovate [®] , Celestoderm [®]	0.05%, 0.1%
	Clobetasone butyrate ²	Eumovate [®]	0.05%
	Desoximetasone ²		0.05%, 0.025%
	Flucinonide ²	Lidex [®] , Lidemol [®]	0.01%, 0.05%
	Diflucortolone valerate		0.1%
	Fluocinolone Acetonide ²	Synalar [®] , Synamol [®] , Derma-Smooth ^{®1}	0.01%, 0.025%, 0.01%
	Mometasone furoate		0.1%
	Prednicarbate		0.1%
Triamcinolone acetonide ^{2,3}	Aristocort D [®] Aristocort R [®] Vioderm-KC ^{®,3} Kenacomb ^{®,3}	0.025% 0.05% 0.1%	

¹ formulary drug (hydrocortisone 1%, betamethasone 0.1%, clobetasol propionate 0.05%)

² all topical corticosteroids will be interchanged to either hydrocortisone 1 % (low potency), betamethasone 0.1% (moderate potency) or clobetasol propionate 0.05% (highest potency) based on potency. Refer to Therapeutic Interchange Policy for Topical Corticosteroids PPO #863.

³ Triamcinolone 0.1% with neomycin, gramicidin, nystatin is formulary

TOPICAL CORTICOSTEROID POTENCY CHART cont'd

Relative Potency	Generic Name	Brand Name	Strength
High Potency	Betamethasone dipropionate ²	Propaderm [®] Diprosone [®] , Diprolene Glycol [®]	0.025% 0.05%
	Halcinonide ²	Halog [®]	0.1%
	Triamcinolone acetonide ²	Aristocort C [®]	0.5%
Highest Potency	Clobetasol propionate ¹	Dermovate [®]	0.05%
	Halobetasol propionate		0.05%

¹ formulary drug (hydrocortisone 1%, betamethasone 0.1%, clobetasol propionate 0.05%)

² all topical corticosteroids will be interchanged to either hydrocortisone 1 % (low potency), betamethasone 0.1% (moderate potency) or clobetasol propionate 0.05% (highest potency) based on potency. Refer to Therapeutic Interchange Policy for Topical Corticosteroids PPO #863.